| __timestamp | Alnylam Pharmaceuticals, Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 7461000 |
| Thursday, January 1, 2015 | 60610000 | 13047000 |
| Friday, January 1, 2016 | 89354000 | 11253000 |
| Sunday, January 1, 2017 | 199365000 | 13933000 |
| Monday, January 1, 2018 | 382359000 | 29514000 |
| Tuesday, January 1, 2019 | 479005000 | 37121000 |
| Wednesday, January 1, 2020 | 588420000 | 67929000 |
| Friday, January 1, 2021 | 620639000 | 118818000 |
| Saturday, January 1, 2022 | 770658000 | 159371000 |
| Sunday, January 1, 2023 | 795646000 | 213894000 |
| Monday, January 1, 2024 | 975526000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing costs is crucial for success. Alnylam Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, BioCryst's expenses grew by approximately 2,800%, albeit from a smaller base, indicating a rapid scaling of operations.
By 2023, Alnylam's SG&A expenses reached nearly $796 million, while BioCryst's expenses were approximately $214 million. This disparity highlights Alnylam's larger operational scale and market presence. Understanding these trends provides valuable insights into how these companies allocate resources to support growth and innovation. As the biotech landscape evolves, monitoring such financial metrics will be key to predicting future industry leaders.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.